FibroGen to Report Second Quarter 2015 Financial Results on August 13, 2015
Conference Call and Webcast Scheduled for 4:30 p.m. ET (1:30 p.m. PT)
Get Alerts FGEN Hot Sheet
Join SI Premium – FREE
SAN FRANCISCO, Aug. 10, 2015 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN), a research-based biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics to treat serious unmet medical needs, today announced that it will report second quarter 2015 financial results on Thursday, August 13, 2015 after market close, and will host a conference call to discuss financial results and provide a business update at 4:30 p.m. ET (1:30 p.m. PT).
Audio Webcast
Interested parties may access a live audio webcast of the conference call via the investor section of the FibroGen website, www.fibrogen.com. It is recommended that listeners access the website 15 minutes prior to the start of the call to download and install any necessary audio software. A replay of the webcast will be available shortly after the call for a period of four weeks.
Dial In Information
Live (U.S. / Canada): (800) 708-4540 |
Live (International): (847) 619-6397 |
Confirmation number: 40444300 |
About FibroGen
FibroGen is a research-based biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics to treat serious unmet medical needs. The company utilizes its extensive experience in fibrosis and hypoxia-inducible factor (HIF) biology to generate development programs in multiple therapeutic areas. Its most advanced product candidate, roxadustat, or FG-4592, is an oral small molecule inhibitor of HIF prolyl hydroxylases, or HIF-PHs, in Phase 3 clinical development for the treatment of anemia in CKD. A second product candidate, FG-3019, is a monoclonal antibody in Phase 2 clinical development for the treatment of idiopathic pulmonary fibrosis (IPF) and pancreatic cancer. For more information please visit: www.fibrogen.com.
CONTACT: Greg Mann FibroGen, Inc. 415-978-1433 [email protected]Source: FibroGen, Inc.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Growth isn't weak enough to truly undercut inflation pressures - BMO
- Synovus Financial (SNV) PT Lowered to $42 at Piper Sandler
- Wipro (WIT) Tops Q1 EPS by 1c
Create E-mail Alert Related Categories
Press ReleasesRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!